While its biological functions remain elusive, CD133 is found to be overexpressed in tumor-initiating cells in several solid tumors, including melanoma, brain, colon, liver, lung, pancreatic, prostate, and ovarian cancers [33,34]. This evidence concerns the gene PROM1 and ovarian carcinoma.